No quarterly revenue total was found in Definium Therapeutics, Inc.'s SEC filings.
Definium Therapeutics, Inc. (DFTX) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. As of Jun 30, 2026 it held $1.1 billion in cash and investments and $36.5 million in total debt.
Revenue
—
Net income
$-158.99M
-271.9% vs year-ago quarter
Operating cash flow
$-52.78M
-78.3% vs year-ago quarter
Free cash flow
—
EPS
$-1.44
-188.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
134.37M
+76.6% vs year-ago quarter
Net cash
$1.05B
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- DFTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1813814
- Former names
- Mind Medicine (MindMed) Inc. (until Jan 12, 2026)
Other Medicinal Chemicals & Botanical Products companies
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$75.1M | -$59.2M | -$47.6M | -$45.7M | -$40.9M |
| Net income | -$159.0M | -$77.1M | -$50.4M | -$67.3M | -$42.7M |
| Diluted EPS | -$1.44 | -$0.71 | -$0.50 | -$0.78 | -$0.50 |
| Operating cash flow | -$52.8M | -$42.6M | -$43.0M | -$29.6M | -$29.6M |
| Total assets | $1.1B | $401.3M | $440.1M | $236.9M | $265.1M |
| Total liabilities | $194.2M | $122.4M | $107.8M | $106.3M | $79.7M |
| Stockholders' equity | $918.7M | $278.8M | $332.3M | $130.6M | $185.4M |
| Cash and investments | $1.1B | $373.4M | $411.6M | $209.1M | $237.9M |
| Total debt | $36.5M | $40.8M | $40.6M | $40.4M | $41.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 24, 2026 | Jun 22, 2026 |
All 504 Definium Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.